Shanghai Best-Link Bioscience LLC has described polymer-drug conjugates comprising a polymer covalently linked to a cytotoxic drug through a linker and its nanoparticles reported to be useful for the treatment of cancer.
Chengdu Kangnuoxing Biopharma Inc. and Keymed Biosciences Co. Ltd. have identified antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates consisting of antibodies covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Molecules that specifically bind to tumor-associated antigens (TAAs) are crucial for the diagnosis and therapy of cancer. In a recent publication in Molecular Therapy: Oncology, researchers from Université de Nantes presented a novel tailored-made affitin for targeting human mesothelin (hMSLN), which is a TAA overexpressed in many solid cancers and targeted by several experimental drugs.
Amphista Therapeutics Ltd. has developed and presented data for AMX-883, a novel orally bioavailable bromodomain-containing protein 9 (BRD9) degradation inducer for acute myeloid leukemia (AML)
treatment.
D3 Bio Inc. secured $108 million in a series B financing round Dec. 9 to support its planned phase III program of lead oral KRAS G12C inhibitor, elisrasib (D3S-001).
Immuse Therapeutics Inc. has described heterocyclic compounds acting as leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer.
Nikang Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2)- and/or CDK4-targeting moiety through a linker reported to be useful for the treatment of cancer.
Prelude Therapeutics Inc. has synthesized tyrosine-protein kinase JAK2 inhibitors reported to be useful for the treatment of cancer, myelofibrosis, essential thrombocythemia and graft-vs.-host disease.
RSS
